Venous thromboembolism (VTE) is a frequent and potentially life-threatening disease. Beyond the initial three months of anticoagulation, it is essential to evaluate accurately the recurrence risk of VTE in order to stop or to prolong oral anticoagulation. In patients with VTE provoked by a major transient risk factor, the risk of recurrence is sufficiently low to warrant anticoagulation discontinuation [1–5]. In contrast, when VTE is unprovoked, the risk of recurrence is high and international guidelines recommend indefinite anticoagulation in patients with a low or an intermediate risk of bleeding [2–7].
